Inclusion Criteria:

- Patients over 18 years old of either sex who have given their informed consent to
participate in the study.

- Patients with a neoplastic process, with a CVC for the administration of anti-tumoral
treatment or any other treatment related to the neoplastic process.

- Patients with a platelet count above 30,000/mm3.

- Patients with no hemorrhagic symptomatology at the time of their inclusion

Exclusion Criteria:

- Patients with a history of clinically evident hemorrhagic episodes and/or with
increased bleeding due to any other homeostatic alteration that contraindicates
anticoagulant treatment and/or in the past two months have presented at least one of
the following: active hemorrhaging or organic lesions susceptible to bleeding (e.g.
active peptic ulcer, hemorrhagic cerebrovascular accident, aneurysms).

- Major surgery in the past two months.

- Known hypersensitivity to LMWH, heparin or substances of porcine origin.

- Patients with congenital or acquired bleeding diathesis.

- Damage to or surgical interventions of the central nervous system, eyes and ears
within the past 6 months.

- Acute bacterial endocarditis or slow endocarditis.

- Patients with a history of heparin-associated thrombocytopenia.

- Patients with severe renal failure (serum creatinine over 2 mg/dl) or hepatic
insufficiency (with values of AST and/or ALT > 5 times the normal value established
by the reference range of the local hospital laboratory).

- Severe arterial hypertension (systolic blood pressure over 200 mmHg and/or diastolic
blood pressure over 120 mmHg).

- Patients with suspected inability/or inability to comply with treatment and/or
complete the study.

- Patients who are participating in another clinical trial or have done so in the past
30 days.

- Patients with a life expectancy less than 3 months.

- Women who are pregnant or breast-feeding, or with the possibility of becoming
pregnant during the study.

- Patients on treatment with anticoagulants or who have been on treatment during the
week previous to insert the CVC (including prophylaxis with heparin for hepatic
veno-occlusive disease).

- Patients diagnosed with acute leukemia or awaiting a transplant from hematopoietic
progenitors during the 90 days of the study.